ONCBeOne MedicinesRunning, no new patients
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
Waldenstrom Macroglobulinemia · Waldenstrom's Macroglobulinemia Recurrent · Waldenstrom's Macroglobulinemia Refractory
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 114 (final count)
- Started
- Oct 23, 2023
- Main results expected
- Sep 22, 2026
- Fully finished
- Aug 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Cohort 1: Major Response Rate (MRR)
Measured over: Up to approximately 4 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05952037 · record last updated 2026-10-20 · checked 2026-11-09 15:47 UTC